Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.

Francesco ArcioniAndrea RoncadoriValeria Di BattistaSante TuraAnna CovezzoliSante CundariCristina Mecuccinull null

Published in: European journal of haematology (2018)

Erythroid response to Lenalidomide was similar in MDS with isolated del(5q) and with del(5q) plus one anomaly. Progression to AML or higher risk MDS showed different cytogenetic features.

Keyphrases

multiple myeloma
newly diagnosed
stem cell transplantation
quality improvement
copy number
high dose
allogeneic hematopoietic stem cell transplantation
acute lymphoblastic leukemia
adverse drug
drug induced